Our results indicate that the engineering of artificial DNA-binding domains (DBDs) linked to DNMT3A can be utilized to promote long-lasting SOX2 silencing and represents a promising therapeutic approach to minimize tumor relapse. Here, DNMT3A is linked to neoplasm.